In HER2-positive breast cancer, fatty acid accumulation due to dyslipidemia also promotes drug resistance via acyl-CoAcholesterolacyltransferase and apolipoprotein E receptors [32]. The gene discussed is LRP1; the disease is metabolic syndrome.